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Objective. Patients with rheumatoid arthritis (RA) are at increased risk of malignant lymphomas with a strong correlation with RA disease severity. Given the changes in RA therapy over recent decades, this study was undertaken to assess whether lymphoma risk remains increased, and if so, to explore risk predictors and lymphoma subtypes.
Methods. We identified 12,656 cases of incident RA in the Swedish Rheumatology Quality Register 1997-2012 and obtained information on therapy and inflammatory activity during the first year after diagnosis. Each patient was matched to 10 population comparator subjects. Through linkage to the Swedish Cancer Register, lymphomas, including subtypes, were identified. We assessed hazard ratios (HRs) using Cox regression.
Results. Overall, the HR for lymphoma was increased in RA, to 1.6 (95% confidence interval [95% CI] 1.2-2.1). Taking RA duration into account, risks did not appear to have declined over successive calendar years of RA diagnosis. Neither use of methotrexate the first year after RA diagnosis nor ever use of tumor necrosis factor inhibitors (TNFi) increased lymphoma risk (HR 0.9 [95% CI 0.4-1.9]). Use of oral corticosteroids the first year after RA diagnosis was associated with a reduced risk (HR 0.5 [95% CI 0.3-0.9]). Inflammatory activity during the first year after RA diagnosis did not predict future lymphoma risk. Chronic lymphocytic leukemia occurred less frequently, and Hodgkin's lymphoma occurred more frequently, in RA patients than in the general population.
Conclusion. The average lymphoma risk in recently diagnosed RA is similar in magnitude to that reported in historical cohorts. Standard antirheumatic treatment including TNFi did not predict future lymphoma risk. Distribution of lymphoma subtypes warrants further investigation.
In rheumatoid arthritis (RA) an increased risk of malignant lymphoma, an average doubling of the risk compared with the general population, is well established (1) (2) (3) (4) . Although the mechanisms underlying this risk increase are not understood (4) (5) (6) (7) , available data suggest a strong association with RA disease severity and accumulated inflammatory activity. Further, we have noted a particularly increased risk of diffuse large B cell lymphoma (DLBCL) (8) during the period 1964-1995 among RA patients who received the antirheumatic treatment regimens (agents and dosages) characteristic of that period. In that population, we also noted a pronounced reduction in risk following treatment with corticosteroids (9) , indirectly suggesting a possible modification of lymphoma risk through antiinflammatory or immunomodulatory treatment.
In light of the dramatic changes in RA treatment over the last decade, toward earlier and more aggressive therapy and more ambitious treatment goals, it is tempting to hypothesize that the risk of lymphoma in contemporary RA patients may have decreased. In a study based on incident RA patients from 1997 to 2006 who were followed up for lymphoma occurrence through 2006, we still observed, however, an overall doubling of the lymphoma risk compared with the general population (10) .
In the present study, based on incident RA from 1997 to 2012, we aimed to update and extend our previous assessments of lymphoma risk, in particular to examine the risk in patients diagnosed as having RA during more recent years, 2007-2012. We further aimed to explore early risk predictors, including RA disease characteristics and therapy, and to investigate whether individual lymphoma risk may be predicted in the first year after RA diagnosis. We also investigated the distribution of lymphoma subtypes in RA and whether this distribution remains different from that in the general population or has changed compared with that observed in historical RA cohorts (8, (11) (12) (13) (14) . To address these objectives, we used data from a large incident RA cohort, a matched general population comparator cohort, linkage to the Swedish Cancer Register, and histopathologic review of lymphoma specimens.
PATIENTS AND METHODS
Study design. This was a population-based nationwide cohort study of patients with RA and matched general population comparators. The main exposures of interest were inflammatory activity and therapy. The outcome was malignant lymphoma.
Setting. The Swedish healthcare system is public and tax funded. Patients with RA are generally diagnosed, treated, and followed up by rheumatologists. The unique personal identification number issued to all Swedish residents and recorded in all health and census registers enables registry linkages. The registers also allow for identification of general population comparator cohorts and enable prospective assessment of lymphoma diagnoses independently of RA. The study was approved by the Stockholm Ethics Review Board.
Study population. National cohort of Swedish patients with incident RA. The Swedish Rheumatology Quality (SRQ) Register, described in detail elsewhere (15) , includes incident RA patients (,18 months of symptom duration at RA diagnosis) $18 years of age who (for the period under study) fulfill the American College of Rheumatology (ACR) 1987 criteria for RA (16) . At RA diagnosis, patients are entered into the register with information on age, sex, rheumatoid factor (RF) status, date of first symptoms, and date of diagnosis of RA. Since information on anti-citrullinated protein antibody (ACPA) status was mainly available for patients with incident RA included after 2010, according to the ACR/European League Against Rheumatism criteria for the classification of RA (17), we did not use this information. Patients are followed up with respect to inflammatory activity and therapy in their respective rheumatology units. For this study, we included all patients in the SRQ Register who were diagnosed as having RA between 1997 and 2012 and had a duration of #12 months between the first RA symptom and the diagnosis. To avoid the possibility that an underlying lymphoma might be misclassified as incident RA, we excluded all person-time and all lymphomas during the first 90 days after RA diagnosis. Thus, individuals with an underlying lymphoma mimicking a diagnosis of RA were excluded.
Information on RA characteristics at baseline and subsequent visits was obtained from the SRQ Register. The 28-joint Disease Activity Score (DAS28) (18) was used to measure inflammatory activity and was recorded at baseline, at 1 year of follow-up, and as a composite measure of DAS28 values during the first year after inclusion in the SRQ Register, registered at 3 different time points (3, 6 , and 12 months). The composite measure was based on the lowest DAS28 value in these 3 time periods. Since these predetermined follow-up visits with the rheumatologist in reality may differ by a few months, a time interval for assessment was allowed as follows: the 3-month visit could occur 30-150 days after inclusion, the 6-month visit could occur 150-270 days after inclusion, and the 12-month visit could occur 270-450 days after inclusion. Since the objective of this study was to assess time trends in risks and to identify early predictors for future risk of developing lymphoma in patients newly diagnosed as having RA, we did not assess lymphoma risk in association with inflammatory activity (DAS28) beyond an RA duration of 1 year. Additionally, for RA patients enrolled in the SRQ Register before ;2006, visits to the treating rheumatologist were less frequent, and the physicians' registration in the SRQ Register was performed in a less structured way. Therefore, we only included DAS28 data for the first year after RA diagnosis for all individuals in this study.
Information on treatment with disease-modifying antirheumatic drugs (DMARDs) and oral corticosteroids during the first year of follow-up and treatment with tumor necrosis factor inhibitors (TNFi) at any time during the entire followup period was retrieved from the SRQ Register.
General population cohort. We randomly selected 10 population comparator subjects for each RA patient from the Swedish Population Register. The comparator subjects were matched to the RA patients by age, sex, and residential area. The comparator subjects had to be alive and residing in Sweden at the time of diagnosis of their corresponding RA patient.
Occurrence and validation of lymphoma diagnosis and subtype. Through linkage to the Swedish Cancer Register 1997-2012 (which includes information on all incident lymphomas according to the International Classification of Diseases, Seventh Revision , with coverage of .95%) (19), we identified all registered cases of lymphoma among the RA patients and the population comparator subjects, including information on the date of diagnosis. Individuals with a history of lymphoma (but not other cancer diagnoses) before the beginning of follow-up were excluded.
Malignant lymphomas were defined as non-Hodgkin's lymphomas (NHLs), including chronic lymphocytic leukemia (CLL), and Hodgkin's lymphoma and were recorded as ICD-7 codes 200, 201, 202, and 204.1. For lymphomas occurring in RA patients (n 5 62), the pathology reports were collected for review of lymphoma subtypes. When the initial lymphoma diagnosis had not been confirmed by a hematopathologist and/or had not been diagnosed according to the World Health Organization (WHO) classification criteria (20) , the paraffin-embedded lymphoma tissues were reviewed and classified according to the WHO criteria by an experienced hematopathologist (CS).
In order to compare the distribution of lymphoma subtypes in RA patients to that in the general population, we used the Swedish National Quality Registers of Lymphoma and CLL (Swedish Lymphoma Register [SLR]) 2000-2010 as the reference population. The SLR was set up in 2000 and includes all patients ages $18 years who were diagnosed as having lymphoma, including CLL, in Sweden. The SLR includes more detailed information on lymphoma subtypes according to the WHO classification criteria than the Swedish Cancer Register. Data are presented in national reports on a regular basis (21) (22) (23) . The coverage of SLR during the period in question is estimated to be ;95% of all lymphomas and CLL in the Swedish Cancer Register (21, 23) . The distribution of lymphoma subtypes in our incident RA cohort was further compared to a historical Swedish RA cohort including prevalent RA lymphoma patients from 1964 to 1995 (8) .
For follow-up of vital status, we accessed the nationwide and virtually complete Cause-of-Death Register and the Swedish Population Register to obtain information on date of emigration and date of death from 1997 to 2012.
Statistical analysis. Lymphoma incidence was calculated from the start of follow-up, i.e., inclusion in the SRQ Register (and the corresponding date for the comparator subjects), until the first of lymphoma diagnosis, death, emigration, or the end of the study period (December 31, 2012). We assessed relative risks as hazard ratios (HRs) derived from Cox regression analysis (SAS version 9), adjusted for age (5-year age categories until age 85 years and a category for .85 years) and sex, using time since inclusion date as the time scale.
HRs for lymphoma were determined overall and separately for sex, age (,50 years, 50-74 years, or $75 years), calendar period of RA diagnosis (1997-2003 or 2004-2012) , and RF status. The role of RA duration (0-,6 years or 6-16 years) was assessed using time-dependent covariates. For certain lymphoma subtypes, we estimated HRs in RA patients versus the general population comparator subjects, taking age and sex into account.
When assessing inflammatory activity, DMARDs, and oral corticosteroids during the first year after RA diagnosis as predictors of lymphoma risk within the RA cohort, all persontime and all lymphomas within the first year of follow-up were excluded. When estimating lymphoma risk in relation to TNFi, we treated TNFi as a time-varying covariate so that patients contributed to the TNF-naive group until the start of the first TNFi and to the TNFi-exposed group thereafter. "Ever exposure" is the main risk model that has been used for assessing the risk of lymphoma in relation to TNFi exposure (24) (25) (26) (27) (28) . In our study, however, 90% of the person-time since first starting TNFi was actually spent on active TNFi treatment.
For all of the treatment analyses, we additionally adjusted for inflammatory activity (composite measure of DAS28) during the first year of follow-up.
RESULTS
Risk of lymphoma in recently diagnosed RA patients with respect to RA duration and calendar period of diagnosis. Characteristics of the incident RA cohort are summarized in Table 1 . Of the RA patients diagnosed in 1998, 35% began receiving methotrexate during the first year after RA diagnosis. The corresponding figure for 2009 was 80%. With regard to oral corticosteroids, 60% of the patients diagnosed in 1998 started oral corticosteroids during the first year after RA diagnosis, compared to 73% of the patients diagnosed in 2009.
In the incident RA cohort, we observed 62 lymphomas during 79,239 person-years, corresponding to a crude incidence of 78 per 100,000 person-years (95% confidence interval [95% CI] 60-100). In the population comparator cohort, there were 380 lymphomas during 776,578 person-years, corresponding to a crude incidence of 49 per 100,000 person-years (95% CI 44-54). Overall, the risk of lymphoma among the RA patients was increased 60% (HR 1.6 [95% CI 1.2-2.1]) ( Table 2 ). The point estimate of the HR for lymphoma was higher .6 years after RA onset than during the first 6 years, and this difference reached statistical significance (P 5 0.01). When the calendar period of RA diagnosis was added to the model (in 1-year intervals), these HRs (Table 3) . Risk of lymphoma in relation to RA characteristics and inflammatory activity during the first year after RA diagnosis. HRs for lymphoma by age at RA diagnosis, sex, and RF status were not substantially different from the overall HR. There was no obvious association between lymphoma risk and DAS28 levels at diagnosis of RA and at 1 year of follow-up after RA diagnosis, although these analyses were hampered by low precision (Table 2) . Similarly, estimating lymphoma risk with respect to accumulated inflammatory activity (DAS28) during the first year of follow-up did not result in significant association with high or low aggregated DAS28 values (Table 4 ). The same was true when the DAS28 components were analyzed individually (data not shown).
Risk of lymphoma in relation to antirheumatic therapy. Of the RA patients with $1 year of follow-up in the SRQ Register who later developed lymphomas (n 5 55), 72% (n 5 40) were treated with methotrexate during the first year after RA diagnosis, compared with 74% (n 5 8,621) of the entire RA cohort with $1 year of follow-up (n 5 11,638), resulting in an HR for later lymphoma in patients who received methotrexate during the first year of 0.9 (95% CI 0.8-1.0). Forty percent (n 5 22) of the 55 patients with lymphomas had been treated with oral corticosteroids during the same period compared with 63% (n 5 7,339) in the entire RA cohort with $1 year of follow-up, resulting in a significantly decreased lymphoma risk associated with corticosteroid therapy (HR 0.5 [95% CI 0.3-0.9]) (Table 4). * Adjusted for age and sex. All hazard ratios (HRs) were determined in comparison with the general population comparator subjects. 95% CI 5 95% confidence interval. † As recorded at the time of inclusion in the Swedish Rheumatology Quality (SRQ) Register. ‡ The HR was not determined (ND) because there were ,5 events. § Levels of inflammatory activity at diagnosis of rheumatoid arthritis (RA; at the time of inclusion in the SRQ Register) were based on the lowest Disease Activity Score in 28 joints (DAS28) in the time period 0-30 days after inclusion in the SRQ Register. ¶ Inflammatory activity after 1 year of follow-up (1 year after inclusion in the SRQ Register). Only person-time and events with $1 year of follow-up were included, i.e., 55 lymphomas in 11,638 RA patients. Levels of inflammatory activity at 1 year were based on the lowest DAS28 in the time period 270-450 days after inclusion in the SRQ Register. The median number of visits during the first year of follow-up was 3 (interquartile range 3-4).
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In a sensitivity analysis, we not only adjusted for age, sex, and inflammatory activity, but also adjusted for concomitant use of antirheumatic therapy (use of methotrexate or corticosteroids during the first year after RA diagnosis [yes/no] and use of TNFi ever during the study period). This resulted in HRs for lymphoma in relation to use of corticosteroids (HR 0.5 [95% CI 0.3-0.8]) and use of methotrexate (HR 0.9 [95% CI 0.9-1.0]) that were similar to those found in the original analysis.
Of all of the patients with RA and lymphoma (n 5 62), 19% (n 5 12) had received TNFi therapy at any time during follow-up compared with 24% (n 5 3,072) of the entire RA cohort (n 5 12,656). In this study, exposure to TNFi therapy was not associated with any increased lymphoma risk (HR 0.9 [95% CI 0.4-1.9]) (Table 4 ). When we additionally adjusted for concomitant use of corticosteroids and methotrexate (during the first year after the diagnosis of RA [yes/no]), this resulted in a largely similar relative risk for lymphoma associated with exposure to TNFi (HR 1.2 [95% CI 0.6-2.4]) ( Table 4) .
Distribution of lymphoma subtypes in the contemporary RA cohort. In the RA cohort studied, CLL comprised a considerably smaller proportion (8%) of * Except for the analysis of tumor necrosis factor inhibitor (TNFi) during follow-up, only person-time and events with $1 year of follow-up were included, i.e., 55 lymphomas in 11,638 patients with rheumatoid arthritis (RA). 95% CI 5 95% confidence interval. † Adjusted for age and sex. Hazard ratios (HRs) associated with treatment were also adjusted for inflammatory activity during the first year after RA diagnosis. ‡ Adjusted for age, sex, inflammatory activity during the first year after RA diagnosis, and concomitant use of antirheumatic therapy (use of methotrexate or corticosteroids during the first year after RA diagnosis [yes/no] and TNFi ever during the study period). § Based on a composite measure of the lowest Disease Activity Score in 28 joints (DAS28) in each time period, i.e., within 0-3 months (visit between day 30 and day 150), within 3-6 months (visit between day 150 and day 270), and within 6-12 months (visit between day 270 and day 450) after inclusion in the Swedish Rheumatology Quality Register. The median number of visits during the first year of follow-up was 3 (interquartile range 3-4). ¶ Includes patients who sometimes had a DAS28 of $3.2, sometimes had a DAS28 of ,3.2, and sometimes had missing information on DAS28 at the different assessment time points during the first year of follow-up after RA diagnosis. # Analysis based on the entire RA cohort (n 5 62 lymphomas and n 5 12,656 RA patients).
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all lymphomas compared with the population from 2000 to 2010 as reflected in the SLR (23%). However, in a formal comparison with the general population comparator subjects, the decreased risk was not statistically significant (HR for CLL 0.5 [95% CI 0.2-1.5]). Conversely, Hodgkin's lymphoma was more common in the RA cohort (16%) compared to the SLR (9.5%) and the historical RA cohort (6%), and the risk of Hodgkin's lymphoma was significantly increased compared with the comparator subjects (HR 4.1 [95% CI 1.9-9.1]). The percentage of lymphomas that were DLBCLs was 33% in the RA cohort in the present study versus 32% in the SLR and 48% in the historical RA cohort (Table 5 ). When we estimated the risk of DLBCL in the RA cohort versus the general population comparator subjects based on the ICD-10 codes (as registered in the Swedish Cancer Register), this resulted in an HR for DLBCL of 1.4 (95% CI 0.9-2.2). We also noted a higher proportion of mantle cell lymphoma in our RA cohort (12%) versus the historical cohort (1.5%) and the SLR (4.5%). For other lymphoma subtypes, there were no major differences between the RA cohort and the SLR (Table 5 ).
DISCUSSION
We found that the overall increase in risk of lymphoma in contemporary and incident RA patients remains largely at the same magnitude as that reported in historical RA cohorts (8, 10, 11, 13, 14) . Whereas the risk increased with longer RA duration, we did not demonstrate any trend toward decreasing risk over successive calendar periods of RA diagnosis, although we acknowledge the collinearity of these 2 factors. There was an inverse association between use of oral corticosteroids the first year and lymphoma occurrence; however, we did not observe any significantly increased risk of lymphoma in association with high inflammatory activity during the first year after RA onset. TNFiexposed RA patients were not at higher risk of lymphoma than TNFi-naive patients. The distribution of lymphoma subtypes in the RA patients partly diverged from that observed in the general population.
Our finding of a reduced lymphoma risk with corticosteroid treatment during the first year after RA diagnosis confirms our observation from the abovementioned prevalent RA population followed up for lymphoma from 1964 to 1995 (9), despite dramatically Table 5 . Distribution of lymphoma subtypes in patients with incident RA 1997-2012, patients in a historical RA cohort 1964-1994, and patients with lymphoma in the general population 2000-2010* different levels of RA disease control and use of antirheumatic therapies in these 2 cohorts. The potential mechanisms of action remain unknown, although corticosteroids have potent antiinflammatory effects. In light of the relatively less frequent occurrence of CLL in our cohort, we cannot exclude the possibility that an incipient CLL may go undetected longer if masked by an alternative explanation for a mild leukocytosis such as corticosteroid therapy.
There is longstanding concern that TNFi agents might induce lymphoma development (29) . Although the majority of observational studies on this topic have not demonstrated an association between TNFi and lymphoma risk (3, 11, 24, (26) (27) (28) 30) , some have (31, 32) . In the present study, we found that there was no increased risk of lymphoma associated with TNFi therapy during the study period. There was also a lack of association between lymphoma risk and methotrexate treatment during the first year after RA diagnosis.
Apart from a strong correlation between disease severity and lymphoma risk in RA, the aggressive DLBCL subtype has been specifically linked to RA (33, 34) , indicating a role for activated peripheral B cells in the etiology of lymphomas in RA (8, 35) . In the present study, the occurrence of DLBCL was as expected compared with the general population but lower compared with that previously reported in a Swedish historical RA cohort, in which DLBCLs comprised almost 50% of all lymphomas (not including CLL) (8) . Additionally, we observed a different distribution of CLL (which was less frequent) and Hodgkin's lymphoma and mantle cell lymphoma (which were more frequent) in our contemporary RA cohort compared with the general population.
In light of the previously reported association between accumulated inflammatory activity during the entire RA disease course and lymphoma risk (8) , our observation that the lymphoma risk in patients who were more recently diagnosed as having RA (and hence received modern, intensive RA management) remains elevated is particularly interesting. Similarly, although a lower proportion of DLBCLs than previously reported may suggest a less skewed distribution of lymphoma subtypes in contemporary RA, this is challenged by the observation of a higher than previously observed proportion and risk of Hodgkin's lymphoma (36) .
Our finding is consistent with a few previous studies showing an increased risk of Hodgkin's lymphoma in RA and other autoimmune diseases (8, 13, 37, 38) . Register-based studies spanning earlier time periods must, however, be interpreted with caution, since a significant proportion of NHLs have been misclassified as Hodgkin's lymphoma, which may inflate these risk estimates. Since we used the current WHO classification of lymphoma and the tumor biopsy specimens in a majority of the cases were reviewed by an expert hematopathologist, such a misclassification is unlikely to explain our finding of an increased risk of Hodgkin's lymphoma. Recent data support the notion that Hodgkin's lymphoma is one of the lymphoma subtypes most strongly associated with chronic inflammation (36) . A possible biologic explanation could thus be that the inflammatory environment and the B cell activation in patients with RA could lead to the development of Hodgkin's lymphoma. Other possible mechanisms behind this link could include genetic susceptibility.
Furthermore, we cannot exclude the hypothesis that the remaining increase in lymphoma risk indicates a shift from disease-related to treatment-related lymphoma risk, although this remains speculation. Additionally, it may also be that despite our efforts to monitor the risk for a sufficiently long time span, the follow-up period for more recently diagnosed patients is still too short to reveal what may eventually develop into a decline in the elevated lymphoma risk. Likewise, the absence of a significant association between inflammatory activity during the first year after RA diagnosis and subsequent lymphoma development might be a consequence of insufficient follow-up time.
Our study has some strengths and limitations. Using the SRQ Register allowed us to identify a large incident RA cohort of patients diagnosed by rheumatologists. It also provided reliable information on inflammatory activity and therapy during the first year after RA diagnosis and on TNFi exposure during the entire study period. The large cohort size enabled assessment of uncommon events like lymphoma, overall and in subsets of patients. The detailed information on RA diagnosis made it possible to estimate risk by time since RA diagnosis and calendar period of RA diagnosis. Inclusion of patients with RA diagnosis during the most recent years allowed assessment of lymphoma risks in a contemporary RA population, although the follow-up is by definition short term. Additionally, we did not have reliable information on disease activity beyond 1 year after RA diagnosis and therefore could not adjust for disease activity or disease severity throughout the entire RA course.
By linkage to the Swedish Cancer Register, capture of lymphoma was independent of RA and was similar for the RA and the comparator cohorts, reducing the risk of misclassification of outcome. However, although the SRQ Register provides a large RA cohort, it may be that patients with a short life expectancy (for 706 HELLGREN ET AL example, those with an advanced cancer) are less likely to be included in a register with an intended long follow-up period. This could lead to an underestimation of the true risks of lymphoma in our RA cohort (but does not explain the nondeclining lymphoma risks over calendar time). Further, we lacked information on potential risk factors (apart from the matching factors) shared by lymphoma and RA, although few such factors are currently known (35, 39, 40) . To conclude, the risk of lymphoma in contemporary RA does not seem to have decreased. Initial use of methotrexate and the use of TNFi agents were not more common among those patients who developed lymphomas in this inception cohort, while oral corticosteroids might be associated with a decreased lymphoma risk. Inflammatory activity during the first year after RA diagnosis was not a predictor of future lymphoma risk. The distribution of lymphoma subtypes in RA differs to some extent from that in the general population.
